Overhaul cancer outcomes by offering precise and personalized treatment and improving quality of life
We have completed MVP and ready to pilot or PoC. We have signed three pilots with major hospital groups in India, UAE.
The product is also being co-innovated by SAP.
17 Million Cancer Patient
US $200 Billion
8 Million Cancer Patient
US $100 Billion
100K Cancer Patient
US $2 Billion
Problem or Opportunity
• The survival or complete cure of cancer patients at later stages is as low as 80%.
• The treatment is inefficient and lack efficacy at later stages.
• Treatment is quite lengthy often over 2 years and often shortage of specialists create lengthy waitlists.
• Over 50% suffer psychologically while on treatment and after and quality of life degrades drastically.
Solution (product or service)
Cancer diagnosis, treatment and maintenance outcomes on patient survival and the quality of life is unacceptably inefficient and low despite being expensive, lengthy and painful journey for a patient.
The long term approach is to construct a precision medicine data platform consisting of real-world evidence data initially and subsequently building novel solutions to provide preventative care, accurate diagnostics and personalized care to overhaul cancer outcomes to improve life expectancy, reduce recurrence rates and improve quality of life of cancer patients. Please
In short term and to begin our strategy is to build a survivorship solution to collect evidences from out patients right from the diagnosis stage till the end of life to help patients survive cancer, improve quality of life and collect behavior of therapy and treatment from patients. This evidence collected would be used to personalize the solution and support being offered to patients to improve outcomes.
Company operating in precision medicine and major global players such as SAP, Orion Health, IBM Watson or Google health are the competitors.
Advantages or differentiators
Besides being cost effective and having customer oriented business model, we provide cloud agnostics platform and tools for tertiary genotypic and phenotypic analysis, a survivorship solution and AL/ML tools for providing precision recommendations at different stages such as diagnosis, treatment and maintenance. However, the biggest differentiation is our solution is localized and customized solution.
Different licensing strategy would be used for different components which would be offered as part of the product catalog.
1- On premise the platform license is based on yearly renewal license cost.
2- Yearly renewal cloud hosted per specialty per hospital and number of patients.
3- AI models yearly production subscription cost.
1-Based on estimated effort of resources.
2-Specialized training based on number of hours.
3-Partnership cost and certification cost.
We have raised 15K Euro in pre-seed funding round and looking for Angel/Seed funding to support business.
We would develop various models to integrate with homecare devices, mobile devices, diagnostic devices and EMR applications to provide preventative care, accurate diagnostics and personalized care. We would licence our models on yearly renewal charges but the pricing will differ for each model.
We would also earn through consulting wherein we would provide training, consulting, certification and partnerships to different companies to earn revenue as well as establish new relationships.
We would expand to global market and our business development strategy would depend on the market dynamics.
Money will be spent on
40% on Business Development, 30% on Innovation and development and 30% on customer support and relationship management.
Offer for investor
It will be decided in investor negotiation however we are open to dilute 10% share for the investment sought.
Top 50 Start up by Dubai Chambers, Dubai.
Selected for Innov8 awards, Arab Health.
We cleared first few rounds in Cedars Sinai accelerator program, Florida, US.